Lotus Resources (ASX: LOT) managing director Keith Bowes joins Small Caps to discuss the company’s path to restart the Kayelekera uranium mine in Malawi.

Kayelekera is described as one of the lowest cost uranium projects to develop globally, with first output targeted for 2024.

Lotus is aligning the operational restart to take advantage of significant uranium demand as the world transitions to net zero.

Articles:
https://smallcaps.com.au/lotus-resources-confirms-high-grade-rare-earths-milenje-prospect/
https://smallcaps.com.au/lotus-resources-hits-uranium-chilumba-satellite-target-considers-expanding-regional-program/

For more information on Lotus Resources:
https://smallcaps.com.au/stocks/LOT/

Lotus Resources (ASX: LOT) managing director Keith Bowes joins Small Caps to discuss the company’s path to restart the Kayelekera uranium mine in Malawi.
Kayelekera is described as one of the lowest cost uranium projects to develop globally, with first output targeted for 2024.
Lotus is aligning the operational restart to take advantage of significant uranium demand as the world transitions to net zero.
Articles: <a href="https://smallcaps.com.au/lotus-resources-confirms-high-grade-rare-earths-milenje-prospect/">https://smallcaps.com.au/lotus-resources-confirms-high-grade-rare-earths-milenje-prospect/</a> <a href="https://smallcaps.com.au/lotus-resources-hits-uranium-chilumba-satellite-target-considers-expanding-regional-program/">https://smallcaps.com.au/lotus-resources-hits-uranium-chilumba-satellite-target-considers-expanding-regional-program/</a>
For more information on Lotus Resources: <a href="https://smallcaps.com.au/stocks/LOT/">https://smallcaps.com.au/stocks/LOT/</a>

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

Small Caps is Australia's #1 site for investor news &amp; information on ASX listed small cap companies. The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts. For more information visit: https://smallcaps.com.au/.

The Small Caps podcast keeps stock market investors informed with the latest news by interviewing directors of ASX listed small cap companies and financial market analysts.

Small Caps

Small Caps is Australia's #1 site for investor news & information on ASX listed small cap companies.

The podcast keeps investors informed by showcasing interviews with directors of ASX listed small cap companies and financial market analysts.

For more information visit: https://smallcaps.com.au/

Lotus Resources (ASX: LOT) looks to restart Kayelekera uranium mine as demand intensifies (w/ Keith Bowes)

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the progress of the company's trial of a potential treatment for the aptly named irritable bowel syndrome (IBS).

The company recently received the go-ahead to enrol patients for the second stage of its pivotal GaRP-IBS trial, which is to be conducted at 5 sites in Melbourne, Sydney and Brisbane.

Anatara has received highly encouraging findings from Stage 1 of the GaRP-IBS clinical trial and Stage 2 of the trial will progress these promising developments to further efficacy claims .

Under the trial guidelines, participants will be randomly placed into two groups to take either the optimum dose of the GaRP product selected from Stage 1 or the placebo.

It is expected that each patient will take approximately three months to complete the trial, which involves a wash-out period and then 8 weeks on the product or placebo.

While IBS is a fairly common issue, with an estimated 5% to 10% of the world's population currently be suffering from the syndrome, many of those people may well be unaware of what the issue is.

April is annual IBS Awareness Month with the aim this year to help destigmatise the different types of syndrome people may be suffering.

Approximately 1 in 5 Australians experience the unpleasant symptoms of irritable bowel syndrome (IBS) at some time.

Articles:
https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/
https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/

For more information on Anatara Lifesciences:
https://smallcaps.com.au/stocks/asx-anr/

Anatara Lifesciences (ASX: ANR) executive chair Dr David Brookes joins Small Caps to discuss the progress of the company's trial of a potential treatment for the aptly named irritable bowel syndrome (IBS).
The company recently received the go-ahead to enrol patients for the second stage of its pivotal GaRP-IBS trial, which is to be conducted at 5 sites in Melbourne, Sydney and Brisbane.
Anatara has received highly encouraging findings from Stage 1 of the GaRP-IBS clinical trial and Stage 2 of the trial will progress these promising developments to further efficacy claims .
Under the trial guidelines, participants will be randomly placed into two groups to take either the optimum dose of the GaRP product selected from Stage 1 or the placebo.
It is expected that each patient will take approximately three months to complete the trial, which involves a wash-out period and then 8 weeks on the product or placebo.
While IBS is a fairly common issue, with an estimated 5% to 10% of the world's population currently be suffering from the syndrome, many of those people may well be unaware of what the issue is.
April is annual IBS Awareness Month with the aim this year to help destigmatise the different types of syndrome people may be suffering.
Approximately 1 in 5 Australians experience the unpleasant symptoms of irritable bowel syndrome (IBS) at some time.
Articles: <a href="https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/">https://smallcaps.com.au/anatara-lifesciences-garp-therapy-trial-extension-treat-irritable-bowel-syndrome/</a> <a href="https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/">https://smallcaps.com.au/ibs-awareness-month-anatara-lifesciences-trial-offers-hope-millions/</a>
For more information on Anatara Lifesciences: <a href="https://smallcaps.com.au/stocks/asx-anr/">https://smallcaps.com.au/stocks/asx-anr/</a>

Anatara Lifesciences (ASX: ANR) reaches milestone in progression of Phase II IBS trial (w/ David Brookes)

Barry Dawes, executive chairman at Martin Place Securities, join Small Caps to share his views on the recent rise in gold and silver prices.

Other topics discussed include various commodities such as copper, iron ore and uranium.
Discussion on currencies such as the US dollar, Japanese yen and Australian dollar.
And some ASX stocks.

To find out about investment opportunities in IPOs and placements visit Cap Raise:
https://capraise.com/

-----------------------

Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

-----------------------

WEBSITE
https://smallcaps.com.au/

PODCAST
https://smallcaps.com.au/podcast/

SOCIAL MEDIA
Facebook: https://www.facebook.com/SmallCapsASX
Twitter: https://twitter.com/SmallCapsASX
LinkedIn: https://www.linkedin.com/company/small-caps/

NEWSLETTER
https://smallcaps.com.au/subscribe/

Barry Dawes, executive chairman at Martin Place Securities, join Small Caps to share his views on the recent rise in gold and silver prices.
Other topics discussed include various commodities such as copper, iron ore and uranium. Discussion on currencies such as the US dollar, Japanese yen and Australian dollar. And some ASX stocks.
To find out about investment opportunities in IPOs and placements visit Cap Raise: https://capraise.com/
-----------------------
Small Caps is Australia's #1 site for market news &amp; information on ASX listed small cap companies.
-----------------------
WEBSITE https://smallcaps.com.au/
PODCAST https://smallcaps.com.au/podcast/
SOCIAL MEDIA Facebook: https://www.facebook.com/SmallCapsASX Twitter: https://twitter.com/SmallCapsASX LinkedIn: https://www.linkedin.com/company/small-caps/
NEWSLETTER https://smallcaps.com.au/subscribe/

Commodity prices breaking out as gold and silver lead the way (w/ Barry Dawes)

Lithium Universe (ASX: LU7) chief executive officer Alex Hanly joins Small Caps to discuss the company’s progress with its plans to support the North American supply chain.

With a strategy focused on Canada’s lithium riches and preferred lithium iron phosphate (LFP) battery technology, Lithium Universe is helping to address the gap in lithium conversion capacity in North America.

The company has pulled together a “dream team” of lithium specialists to drive its multi-faceted strategy in what is one of the most active battery metal markets in the world.

A major surge in battery manufacturing is anticipated in North America, with more than 20 major manufacturers planning to deploy an estimated 1,000GW of battery capacity.

At the same time Canada has been rated as the number one jurisdiction in BloombergNEF's Global Lithium-Ion Battery Supply Chain Ranking.

A key component of Lithium Universe’s mine-to-battery-grade lithium carbonate strategy is its advancing Québec Lithium Processing Hub (QLPH).

Articles:
https://smallcaps.com.au/lithium-universe-pivotal-role-closing-north-americas-conversion-gap/
https://smallcaps.com.au/lithium-universe-selects-becancour-port-spodumene-imports-quebec-refinery/
https://smallcaps.com.au/lithium-universe-secures-prime-industrial-property-quebec-hub/

For more information on Lithium Universe:
https://smallcaps.com.au/stocks/asx-lu7/

Lithium Universe (ASX: LU7) chief executive officer Alex Hanly joins Small Caps to discuss the company’s progress with its plans to support the North American supply chain.
With a strategy focused on Canada’s lithium riches and preferred lithium iron phosphate (LFP) battery technology, Lithium Universe is helping to address the gap in lithium conversion capacity in North America.
The company has pulled together a “dream team” of lithium specialists to drive its multi-faceted strategy in what is one of the most active battery metal markets in the world.
A major surge in battery manufacturing is anticipated in North America, with more than 20 major manufacturers planning to deploy an estimated 1,000GW of battery capacity.
At the same time Canada has been rated as the number one jurisdiction in BloombergNEF's Global Lithium-Ion Battery Supply Chain Ranking.
A key component of Lithium Universe’s mine-to-battery-grade lithium carbonate strategy is its advancing Québec Lithium Processing Hub (QLPH).
Articles: <a href="https://smallcaps.com.au/lithium-universe-pivotal-role-closing-north-americas-conversion-gap/">https://smallcaps.com.au/lithium-universe-pivotal-role-closing-north-americas-conversion-gap/</a> <a href="https://smallcaps.com.au/lithium-universe-selects-becancour-port-spodumene-imports-quebec-refinery/">https://smallcaps.com.au/lithium-universe-selects-becancour-port-spodumene-imports-quebec-refinery/</a> <a href="https://smallcaps.com.au/lithium-universe-secures-prime-industrial-property-quebec-hub/">https://smallcaps.com.au/lithium-universe-secures-prime-industrial-property-quebec-hub/</a>
For more information on Lithium Universe: <a href="https://smallcaps.com.au/stocks/asx-lu7/">https://smallcaps.com.au/stocks/asx-lu7/</a>

Lotus Resources (ASX: LOT) looks to restart Kayelekera uranium mine as demand intensifies (w/ Keith Bowes)

In 1 playlist(s)

Small Caps

Social links

Follow podcast

Recent clips